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Abstract
In vitro and in vivo models are widely used in cancer research. Characterizing the similarities and differences between a
patient’s tumor and corresponding in vitro and in vivo models is important for understanding the potential clinical relevance
of experimental data generated with these models. Towards this aim, we analyzed the genomic aberrations, DNA
methylation and transcriptome profiles of five parental tumors and their matched in vitro isolated glioma stem cell (GSC)
lines and xenografts generated from these same GSCs using high-resolution platforms. We observed that the methylation
and transcriptome profiles of in vitro GSCs were significantly different from their corresponding xenografts, which were
actually more similar to their original parental tumors. This points to the potentially critical role of the brain
microenvironment in influencing methylation and transcriptional patterns of GSCs. Consistent with this possibility, ex vivo
cultured GSCs isolated from xenografts showed a tendency to return to their initial in vitro states even after a short time in
culture, supporting a rapid dynamic adaptation to the in vitro microenvironment. These results show that methylation and
transcriptome profiles are highly dependent on the microenvironment and growth in orthotopic sites partially reverse the
changes caused by in vitro culturing.
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on the biological affects that result from perturbation of those
targets in relevant in vitro and in vivo preclinical models. The closer
those model systems are to the human disease, the greater the
chance that those models will be predictive of clinically useful
therapeutic agents. Others and we have previously shown that
GBM-derived glioma initiating or GSCs more closely recapitulate
the genotype and biology of primary human GBMs than do
standard glioma cell lines [21–25]. Nevertheless, there are clearly
some differences between parental tumors and derived cell lines at
the DNA methylation and mRNA expression level [3]. Exactly
how closely GSCs retain the genotype and epigenomic profile of
their parental tumors after serial passage in in vitro and in vivo,
however, is unknown.
In order to better understand the genomic and epigenomic
changes that occur following the passage of GSCs in vitro and in
vivo, we analyzed the genetic alterations, genomic methylation and
the transcriptome profiles of several primary human GBM-derived
GSCs in vitro and in vivo. We demonstrated that although the GSCs
maintain similar genomic and epigenomic characteristics with

Introduction
Glioblastoma Multiforme (GBM) is the most common and
deadly primary brain tumor of the central nervous system.
Developing experimental model systems that accurately recapitulate human tumor biology is critical for understanding the
molecular pathogenesis of the disease as well as for developing and
screening new therapeutics [1–7].
Completion of the human genome project and recent developments in high throughput molecular technologies have enabled the
detailed genomic, epigenomic and transcriptome profiling of
thousands of tumors in unprecedented detail. Specifically, a
number of groups have used high resolution arrays to analyze the
genomic aberrations [8–11], methylation alterations [12–16] and
mRNA expression changes [17–20] found in human GBMs.
Through the characterization of these genomic and epigenomic
abnormalities comes not only an increased understanding of the
biology of these tumors but also the potential of identifying new
therapeutic targets. The validation that a given genetic aberration
and/or a physiological process is a viable therapeutic target rests
PLOS ONE | www.plosone.org
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status of these samples with targeted sequencing and could not
detect IDH1 R132 mutation.

their parental tumors, the in vitro and in vivo microenvironments
exert profound, but partially reversible changes on the methylation
and gene expression profiles of each GSC line. These data reveal
that not only are the types of cells used important, but also how
those cells are grown is pivotal for accurate modeling of the human
disease.

SNP Arrays and Data Set
QIAamp DNA kit (Qiagen) was used to prepare the genomic
DNA from patient tumors, cultured GSCs and Xenografts.
QIAamp DNA Blood Mini Kit (Qiagen) was used to prepare
DNA from patient reference blood. Prepared DNA was hybridized
onto arrays according to the manufacturer’s recommendations
(Affymetrix Human SNP array 6.0 and CytoScan HD array).
After hybridization, the arrays were stained on the Affymetrix
GeneChip fluidics station 450 and scanned at high resolution using
the GeneChip Scanner 3000 7G.
Constructed CEL files were imported using Nexus (version 6.1).
SNP-FASST2 segmentation was used for segmentation with
1000 Kbp as the maximum contiguous probe spacing and three
as the minimum number of probes per segment. The significance
threshold for segmentation was set at 5.0E-7. SNP-FASST2
Segmentation Algorithm is an extension of the FASST2 Segmentation Algorithm. FASST2 Segmentation Algorithm is a Hidden
Markov Model (HMM) based approach that uses many states to
cover more possibilities, such as mosaic events, and then make
calls based on a second-level threshold. With the SNP-FASST2
algorithm, B-allele frequency probes are assigned to a range of
possible states, which are used to make the final copy number and
allelic event calls. The log ratio thresholds for single copy gain and
single copy loss were set at 0.3 and 20.35, respectively. The log
ratio thresholds for two or more copy gain and homozygous loss
were set at 0.7 and 21.1, respectively.

Materials and Methods
Ethics Statement
Human brain tumor specimens are studied under the Protocol#
02C0140, ‘‘A Prospective National Study to Molecularly and
Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative’’ approved by the Institutional Review
Board of National Cancer Institute (FWA#00005897/
IRB#00000001). Written informed consent from the donor or
the next of kin was obtained for use of this sample in research and
samples were maintained according to the NCI Institutional
Review Board Regulations.
The animal research in this study was carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health. The protocol (ASP NOB001) was approved by the
National Cancer Institute Animal Care and Use Committee on
the Ethics of Animal Experiments of NIH. All intracranial
injection and procedures were performed under KetamineXylazine combination anesthesia, and all efforts were made to
minimize suffering.

Patient Samples
DNA Methylation Arrays and Data Set

Five different GBMs were used for this study and were obtained
from surgical samples based on a prospective NCI intramural
clinical tissue acquisition trial. These samples were provided as
snap frozen sections. Pathological diagnosis of these samples was
determined by the local institutional neuropathologist and
centrally reviewed by two NIH neuropathologists according to
WHO criteria [26].

DNA from cell pellets and fresh frozen tumor tissue was
extracted with QIAmp DNA Micro Kit (Qiagen). One microgram
of the DNA was bisulfite converted and processed on Human
Methylation450 BeadChips (Illumina) using the Infinium HD
Methylation Assay. Image data were extracted and analyzed using
the GenomeStudio v2011.1 methylation module (Illumina).
Methylation sites, which have detection p-value greater than
0.05 for any sample or have a missing value for any sample, were
filtered out. We also filtered out methylation sites that reside on sex
chromosomes to eliminate gender effect. 459,913 methylation sites
remained after filtering. We ran batch controls for the batches that
include five parental tumors-GSC pairs and did not detect a batch
effect based on principle component analysis (PCA). We did not
use batch controls for in vitro-in vivo-ex vivo triplicates based on this
result and previous experience in our lab [27].

Glioma Stem Cells and Xenografts
Tumor cells were washed and enzymatically dissociated into
single cells within three hours of surgical removal. NBE media,
which consists of Neurobasal media (Invitrogen), N2 and B27
supplements (0.56 each; Invitrogen), human recombinant bFGF
and EGF (50 ng/ml each; R&D Systems) was used to culture
glioma stem cells (GSCs) (for details [21]).
For xenografts, GSCs were resuspended in 2 ml of HBSS and
injected intracranially using stereotactic techniques into severe
combined immunodeficiency mice (SCID/NCr mice with BALB/
c background, female, aged 3 months, and weighing around 20–
22 g, obtained from Charles River, Frederick, MD), according to
animal study proposal approved by NCI Animal Use and Care
Committee. Intracranial tumors were resected and resected tissues
were used as in vivo samples. Portion of resected tissues were
cultured again in the same media to develop the ex vivo samples.
Xenograft samples and ex vivo cell cultures were controlled for
mouse contamination by real time genomic PCR of either mouseor human-specific GAPDH probe set (Applied Biosystems,
Cat#4308313 or Cat#402869) and only samples that showed
no detectable mouse tissue (or cell) contamination were used in
subsequent analyses.
We predicted the G-CIMP status of each sample using our
previously published prediction method [27]. We determined all
samples as G-CIMP negative. Moreover we checked the IDH1
PLOS ONE | www.plosone.org

mRNA Expression Arrays and Data Set
RNA was isolated and purified from cell pellets and fresh frozen
tumor tissue using TRIZOL (Invitrogen) and PureLink RNA Mini
Kit (Invitrogen). Affymetrix GeneChip Command Console
(AGCC) was used to create the raw mRNA expression data
(CEL files). We imported data to Partek Genomics Sofware
(version 6.6, Partek Inc., St. Charles, MI) and normalized samples
using RMA defaults (RMA background correction, quantile
normalization, and median polish).

Hierarchical Clustering (HC) and Principle Component
Analysis (PCA)
We used Partek Genomics Software (version 6.6, Partek Inc., St.
Charles, MI) to perform HC and PCA. Agglomerative (bottom-up)
approach, complete linkage and Euclidean distance were used for
all HCs. Expression data were standardized for each column
2
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Figure 1. Copy number alterations for patient tumors and in vitro, in vivo, ex vivo GSC samples. (A) Comparison of five matched patient
tumors and their corresponding in vitro GSCs. Each line represents a sample. Three or four digit code represents GSC id, PT represents patient tumor
and invitro represents in vitro GSC. Blue is amplification, red is deletion, purple is loss of heterozygosity and orange is allelic imbalance. Examples of
the many differences between PTs and matched in vitro GSCs are loss on chromosome 13 at GSC-827 and gain on chromosomes 4, 8, 9 and 14 at
GSC-1228. (B) Comparison of in vitro-in vivo-ex vivo triplicates for early and late passages of two GSCs.
doi:10.1371/journal.pone.0094045.g001

matched patient tumor and in vitro GSCs (passage 10). We
observed that there were some significant differences between
genomic profiles of patient tumors and their corresponding GSCs
(Figure 1A). These differences might be due to selective growth
and/or loss of certain tumor sub-clones or acquisition of new
aberrations in culture.
We next compared early and late passage (5 and 18,
respectively) in vitro GSCs, the in vivo xenografts they formed and
the GSCs cultured from those dissected xenografts (‘‘ex vivo’’). We
observed that the genomic profiles in all matched samples were
nearly identical (Figure 1B), consistent with our prior characterization of GSCs [21]. Based on these results, it appears that the
initial selection of clonal subtypes in culture plays a major role in

(probe set) prior to performing the HC, although this was not done
for the methylation data. PCAs were performed using correlation
dispersion matrix and normalized eigenvector scaling.

Results
Comparison of genomic aberrations
We used Affymetrix SNP6.0 and Cytoscan HD arrays to
measure the genomic aberrations in our parental tumors (PTs),
matched cultured GSC lines (in vitro) and GSC-generated
xenografts (in vivo). To determine somatic changes, for each
sample we subtracted background using blood DNA arrays from
the same patient. First, we compared the genomic profiles for five

PLOS ONE | www.plosone.org
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Figure 2. DNA methylation profiles for patient tumors and in vitro GSCs. (A) Principle Component Analyses (PCA) of 3847 methylation sites
with standard deviation more than 0.35. PT represents patient tumor and in vitro represents the corresponding in vitro GSCs. Matched PT-in vitro
pairs are connected with lines. (B) Median methylation values for each sample based on selected 3847 sites.
doi:10.1371/journal.pone.0094045.g002

Mann-Whitney test and retained 163,959 out of 459,913
methylation sites, which were not differentially methylated
between GSCs 827 and 923 (p-value.0.5). Out of these sites,
we present 6825 sites with standard deviation greater than 0.15 as
HC and PCA (Figure 3A, 3B, S2).
We observed that ex vivo samples were clustered between in vitro
and in vivo samples, which points to the partial recovery of microenvironmental associated changes in just a few passages
(Figure 3A). Ideally, ex vivo samples were expected to cluster more
closely to the in vitro samples, but perhaps since ex vivo samples
spent less time in culture, they were not clustered tightly with in
vitro samples (Figure 3A). GSCs derived from ex vivo samples,
however, were much closer to in vivo samples, which might be due
to less time in culture. We also observed that the changes seen with
serial passage in vitro or through growth in vivo were highly similar
between GSC lines derived from different patients (Figure 3B).
Finally, we found that xenografts from early passage GSCs
arewere much clustered together with PTs and xenografts from
late passage GSCs were clustered with late passage ex vivo samples
suggesting that the time in culture has an important effect on
overall methylation profile. (Figure 3A, Figure 3C). The differences that were seen between xenografts and PTs (Figure 3B)
could be the result of influence of mouse versus human brain
microenvironments, the time that GSCs spent in culture before
xenotransplantation, or the selection of specific xenograft-generating GSCs.
When we compared the median methylation values for all 827
and 923 samples, we observed that PTs and in vivo samples have
lower median methylation levels than their corresponding in vitro
and ex vivo samples (Figure 3C). We also observed that later
passage in vitro (ex vivo) samples have much higher median
methylation levels than earlier passage in vitro (ex vivo) samples. The
differences between early and late passage in vivo samples,
however, were much smaller than their corresponding in vitro
GSCs, suggesting that the hyper-methylation seen with extended
passaging is highly reversible.

the copy number differences between patient tumors and GSCs,
after which copy number alterations remain remarkably stable
whether serially passaged in vitro or in vivo.

Comparison of genomic DNA methylation
We used the Illumina Infinium 450K platform to assess
methylation profiles of our samples [28,29]. This platform
measures methylation level for a methylation site as a continuous
value between 0 and 1. It compares the methylated and
unmethylated probe intensities on bisulfite treated DNA. For
our analysis, we included five PT-in vitro pairs, four in vitro-in vivo-ex
vivo triplicates and three non-tumor brain (epilepsy) samples. In
first part of the analyses, we focused on potential changes between
non-tumor brain tissues, patient tumors and in vitro GSCs.
Figure 2A represents the summation of the methylation analyses
through a PCA of 3847 methylation sites with standard deviation
greater than 0.35. This figure demonstrates that all GSCs have
significantly lower values in the first principal component (x-axis),
which represents more than 60% of the variation. This suggests
that there is a systematic change between PTs and in vitro GSCs.
We also observe that all three non-tumor samples cluster together
at the upper-right end of the plot completely away from the PTs
and the GSCs. We checked the median methylation values to see
whether methylation changes observed in in vitro GSCs is
associated with an overall hypo- or hyper-methylation. We
detected significant hyper-methylation in cultured cells, which
was consistent for all five PT-in vitro pairs (Figure 2B). We also used
HC to assess the similarity of samples and to validate our PCA
results (Figure S1). In HC, 5 PTs with epilepsy samples and 5 in
vitro GSCs clustered as two separate groups, which confirmed PCA
results.
In the next part of our analyses, we focused on the differences
between in vitro and in vivo models. For better assessment of the
data, we removed the differentially methylated sites between two
GSC models that we used in our analyses. Along this aim, we ran a

PLOS ONE | www.plosone.org
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Figure 3. DNA methylation profiles of patient tumors and in vitro, in vivo, ex vivo GSCs for two cell lines. (A,B) HC and PCA for PT, in vitro,
in vivo and ex vivo samples for early and late passages (ep, lp). 6825 sites with standard deviation greater than 0.15 are presented. These sites are not
differentially methylated between 827 and 923 (Mann-Whitney p-value more than 0.5). (C) Median methylation values for each sample based on
selected 6825 sites.
doi:10.1371/journal.pone.0094045.g003

between PTs and their corresponding xenografts. Thus, it appears
that xenografts partially recover the gene expression profiles seen
in the original PT. Finally, when we compared the median
expression values, we observed that PTs and in vivo samples have
higher expression levels compared to matched in vitro and ex vivo
samples (Figure 4C).
When we looked at the methylation and expression data in total,
we observed that PT and in vitro GSCs are very different in both
data sets. By contrast, the PT samples were much more similar to
in vivo xenografts than in vitro samples in both data sets.

Comparison of Transcriptomes
We compared seven matched PT-GSC pairs and four in vitro-in
vivo-ex vivo matched samples at the transcriptome level using
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays. We
used U87 cells as replicates in different batches to control for
changes due to technical artifacts. All U87 replicates clustered
together in HC and PCA, which confirmed the quality of the
results (Figure S3, S4). Next, we removed U87 replicates and
imported remaining samples with into Partek with RMA
normalization and filtered in high variation (st. dev. .1.3) 1901
probe sets (out of 54,678). The HC of these probe sets is
represented in Figure 4A for five PT-in vitro GSC pairs (GSCs are
passage 10 and three replicates were used), which demonstrates a
clear separation between these two groups. Figure 4B and 4D
represent HCs for PT, in vitro, in vivo, ex vivo samples for 827 and
923 samples, respectively. These HCs demonstrate a clear
separation between PTs and in vitro GSCs, but a relative similarity

PLOS ONE | www.plosone.org

Detailed Analyses for Differentially Methylated and
Expressed Genes
We next explored which genes demonstrated significant
differences between five paired PT and in vitro GSCs both in
DNA methylation and mRNA expression. We selected
22,264 (5408 genes) out of 459,913 methylation sites based on a
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Figure 4. Trancriptome data for high variation (std. dev. .1.3) 1901 probe sets. (A) HC for matched PT-in vitro pairs for five GSC lines. (B)
HC for PT and in vitro-in vivo-ex vivo triplicates for early and late passage 827 samples (C) Median expression values for all samples. (D) HC for PT and
in vitro-in vivo-ex vivo triplicates for early and late passage 923 samples.
doi:10.1371/journal.pone.0094045.g004

non-parametric paired Quade test with Benjamini-Hochberg
FDR,0.05 and mean methylation difference greater than 0.3.
Similarly we ran a paired t-test and picked 645 differentially
expressed genes with Benjamini-Hochberg FDR,0.05 and
absolute fold change greater than three. The intersection between
these gene sets demonstrated 238 differentially methylated and
differentially expressed genes (Table S1). Figure 5 demonstrates
these genes with mean methylation differences (y-axis) and fold
changes (x-axis). Data points are colored red if it is a part of a CpG
island and blue if it is not (all genes in Figure S5). We observed that
the majority of differentially methylated and differentially
expressed genes were hyper-methylated and down-regulated in
in vitro GSCs. Furthermore, a significant proportion (p-value,0.0001 Chi-Squate test with Yates correction) of the hypermethylated sites occured within CpG islands (365/802) while
hypo-methylated sites rarely occur within CpG islands (2/78).
Next, we categorized methylation sites with respect to their
locations on genes as TSS1500 (site location is between 1500 and
200 bases upstream of transcription start site (TSS)), TSS200 (site
location is within 200 bases upstream of TSS), 59 UTR, 1st Exon,
Body (except 1st exon) and 39 UTR. Out of the 64,671 sites in
TSS1500, 3536 (5.47%) are differentially methylated. Similarly;
4.74%, 4.72%, 4.15%, 4.02% and 3.82% of the sites in the 1st
Exon, 59 UTR, Body, TSS200 and 39 UTR are differentially
methylated. This shows that sites in the promoter, but not in the
PLOS ONE | www.plosone.org

immediate vicinity of TSS, were preferentially targeted for
methylation changes in vitro. Next, for methylation sites associated
with genes, we measured which portion of differentially methylated genes is also differentially expressed. Out of the differentially
methylated sites within each region, 7.18%, 7.00%, 6.69%,
5.32%, 4.73% and 3.63% are also differentially expressed in 59
UTR, 1st Exon, TSS200, TSS1500, Body, and 39 UTR,
respectively, which shows stronger methylation-expression interaction near TSS.
Since CpG islands are very important in terms of DNA
methylation, we categorized methylated sites according to their
location with respect to CpG islands. We defined four categories as
Island, Shore (0–2000 base pairs to Island), Shelf (2000–4000 base
pairs to Island) and Rest and assigned each site to one of these
categories. We observed that 7.03%, 5.60%, 3.27% and 2.22% of
the sites are differentially methylated in Island, Shore, Rest and
Shelf categories, respectively. This shows that sites located in or
close to CpG Islands are more sensitive to in vitro changes. Then,
we measured which percent of the differentially methylated genes
are differentially expressed within each region. We observed that
5.78%, 3.33%, 1.34% and 0.40% of the differentially methylated
sites within Island, Shore, Rest and Shelf categories are also
differentially expressed, respectively. This suggests that methylation-expression regulation is stronger in CpG islands.
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Figure 5. Fold changes (x-axis) and mean methylation differences (y-axis) between paired in vitro-PT pairs for both differentially
expressed and differentially methylated genes. Differentially expressed genes determined with paired t-test. Genes with false discovery rate
less than 0.05 (Benjamini-Hochberg) and absolute fold change greater than three are used. Differentially methylated sites determined with paired
non-parametric Quade test and sites with false discovery rate less than 0.05 (Benjamini-Hochberg) and absolute methylation difference greater than
0.3 are used.
doi:10.1371/journal.pone.0094045.g005

A subset of GBM samples are categorized as G-CIMP due to
the hyper-methylation profile they display [12]. This hypermethylation profile is tightly associated with a mutation in IDH1
[14]. We, therefore, checked whether the methylation sites, which
show differences between G-CIMP positive, and G-CIMP
negative GBMs, were also differentially methylated between
parental tumors and in vitro samples. To this point, we analyzed
368 TCGA samples from our previous study [27]. There were
21,587 methylation sites shared between that data set and the data
set we used for this study. Among these, 936 and 854 sites were
differentially methylated between G-CIMP positive and negative
samples (Mann-Whitney, Benjamini-Hochberg FDR,0.05 and
mean methylation difference .0.3) and between parental tumors
and in vitro samples (Quade, Benjamini-Hochberg FDR,0.05 and
mean methylation difference .0.3), respectively. 271 sites were
shared between two comparisons. When we ran a Chi-Square test
with Yates correction on these numbers, we observed that
differentially methylated sites in the two comparisons were
associated (p-value,0.001). This suggests that certain sites have
a tendency for methylation changes regardless of the specific
genetic or environmental context.
Finally, we analyzed the in vitro differentially methylated and
differentially expressed 238 genes with fold changes using
Ingenuity Pathway Analyses software for functional enrichment.
We observed development and cancer related categories such as
‘‘Hematological System Development’’, ‘‘Cancer’’, ‘‘Cellular
Development’’ and ‘‘Cell Death and Survival’’ as the most
enriched categories (Figure S6).

PLOS ONE | www.plosone.org

Genes potentially involved in GSC DNA hypermethylation in vitro
Serial cell passage in vitro is known to change the methylation
profiles of cultured cells [30–32]. We confirmed this finding in this
study as we observed hyper-methylation in in vitro samples
compared to PTs and progressive hyper-methylation with serial
passage in vitro. To identify the potential genes that might be
related to this in vitro hyper-methylation phenotype, we compared
the expression levels of genes encoding proteins with ‘‘methylation’’ functions based on Gene Ontology (GO) categories [33]. We
identified 220 genes (out of 21,121 genes in our data set) within
this category. In a paired t-test comparing five different matched
PTs and in vitro GSCs, we identified 12 differentially expressed
genes with FDR less than 0.03. These genes are ATF7IP,
BCDIN3D, DNMT1, ELP2, GATAD2A, GSPT1, MTA2,
N6AMT1, NTMT1, PRMT5, TPMT and WDR5. In a similar
fashion, we ran paired t-tests between four matched in vitro-in vivo
and in vivo-ex vivo pairs. We obtained 89 and 77 differentially
expressed methylation-related genes, respectively with p-value less
than 0.03 (FDR,0.23). ATF7IP, ELP2, NTMT1, PRMT5 and
TPMT are the five genes that were present in all three
comparisons. Among these genes, PRMT5 has been recently
reported to cause DNA methylation changes [34]. PRMT5
mediates methylation of histone H4R3, which recruits DNMT3A
resulting in DNA methylation and repression of gene expression.
Consistent with this, we observed clear differences between PT-in
vitro and in vitro-in vivo pairs for PRMT5 expression (Figure S7).
These results suggest that up-regulation of PRMT5 expression in
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methylation (Figure 3A) and mRNA expression (Figure 4B, 4D)
datasets. We also detected significant and consistent differences
between PTs and in vivo xenografts. One potential reason for this
could be contamination of normal human or mouse brain tissue.
To exclude this potential problem, we applied strict contamination
controls as measured by qRT-PCR for human and mouse specific
probes, and only used samples with no detectable (or negligible)
contamination. Thus, it is again likely that the differences seen
between the expression and methylation profiles of the PTs and
their corresponding xenografts are either due to initial elimination
of certain PT cells in culture, selection of specific clones most
adapted to growth in the murine central nervous system
microenvironment and/or the biological adaptation of the tumor
to the selective pressures of that unique microenvironment.
In our previous study, we have demonstrated that NBE grown
GSCs are better representative of human GBMs than matched
cells gown in serum or standard glioma cell lines [21]. In this
study, we further define the limits of the GSC model for
reproducing the biology of the human disease. The mechanisms
driving these differences are beyond the scope of this report and
additional studies examining the potential role of individual clones
or cellular subpopulations in vitro cultures and in vivo will be
necessary. Nevertheless, through the continued refinement of
models such as these and through our increased understanding of
the strengths and limitations of such models, will come a better
tool for understanding GBM biology and more accurate predictive
screening of novel therapeutic strategies.

vitro may partially contribute to the genomic hyper-methylation
seen in GSCs with serial passage in vitro.

Discussion
In this study, we characterized the genomic aberration, DNA
methylation and mRNA expression profiles of parental GBMs
with their matched in vitro and in vivo GSCs that they generate.
Although earlier studies have addressed some aspects of the
differences between parental tumor and their matched tumor cell
lines, our study is one of the first to use high-resolution arrays to
profile multiple dimensions of the genomic, methylation and
transcription machinery in detail. Our results show that DNA
methylation and mRNA transcription undergo significant and
reproducible transformation from in vitro to in vivo growth
conditions and then back again. These changes were seen when
comparing PTs to their corresponding GSCs in vitro, and were
partially reversed when those same GSCs formed xenograft
tumors in the brains of immunodeficient mice. When we cultured
GSCs from those same xenograft tumors, we observed a quick
reversion back to the original in vitro GSC-related expression
profiles within a few passages, with a much slower and less
complete recovery of their methylation profiles. In summary, our
observations demonstrate that GSCs quickly adapt to their
microenvironment by changing their transcriptome and epigenome.
We observed a reduction in the overall mRNA expression levels
in in vitro GSCs compared to PTs and in vivo GSCs. The reasons for
this are unclear but are likely multifactorial. One possibility might
be due to down-regulation in vitro of a number of pathways, which
normally responsive to the diverse extra-cellular-signaling environment found in vivo. Another possibility rests on the observation
made by others and us that GSC mediated xenograft formation
requires high levels of c-myc in vivo in contrast to in vitro GSC
proliferation that requires much lower levels [35]. Given the
recent demonstration of c-myc as an enhancer of overall
transcriptional levels throughout the genome [27], lower levels
of c-myc activity in in vitro GSCs may contribute to the overall
lower mRNA transcriptional levels in in vitro. Finally, the
progressive increase in genomic methylation that others and we
observed with serial passage of our GSCs may be representative of
and/or contribute to an overall increase in the heterochromatin
content of the genome of in vitro passaged GSCs thereby resulting
in a reduction in mRNA expression.
Our data demonstrate the adaptation of glioma cells to their
microenvironment but it does not explain the mechanism of
adaptation. One possibility is that the selective pressures of the
given microenvironment (in vitro or in vivo) can select for an
adaptive phenotype and genotype most advantageous for those
pressures. Another, non-mutually exclusive possibility, is based on
the fact that GBMs and GSC lines are made up of highly
heterogeneous clones of tumor cells and genomic profiles obtained
from tumors represent only an averaged result for potentially
innumerable clones. Individual clones may be selected for by in
vitro and in vivo selective pressure causing a dominant clone(s), with
its corresponding genotype and phenotype, to dominate. The
existing data do not allow us to definitively discriminate between
these two possibilities although it is likely that both mechanisms
play a role in explaining the changing profiles seen between the
different growth conditions. Further studies to examine the clonal
distribution will be required to explain the mechanistic basis for
how GSCs adapt to their microenvironment.
In our analyses, we observed that in vivo xenografts were
clustered between PTs and in vitro/ex vivo samples in HCs on DNA
PLOS ONE | www.plosone.org

Supporting Information
Figure S1 Hierarchical Clustering of methylation sites
for non-tumor, patient tumor and in vitro, in vivo and ex
vivo samples. 3847 sites with standard deviation greater than
0.35 are presented. First column represents the type of sample and
second column represents the GSC code. Each cell in the heat
map is colored by the methylation rate; bright blue is 0% and
bright red is 100% methylation.
(DOCX)
Figure S2 Hierarchical Clustering for non-tumor, patient tumor, in vitro, in vivo and ex vivo samples. 6825
sites with standard deviation greater than 0.15 are presented.
These sites are not differentially methylated between 827 and 923
(Mann-Whitney p-value more than 0.5). First column represents
the type of sample and second column represents the GSC code.
Each cell in the heat map is colored by the methylation rate; bright
blue is 0% and bright red is 100% methylation.
(DOCX)
Figure S3 PCA for PT, in vitro, in vivo, ex vivo and U87

mRNA profiles. Samples are imported with RMA and 3002/
54678 probe sets with standard deviation greater than 1.3 are
presented.
(DOCX)
Figure S4 Hierarchical clustering for PT, in vitro, in
vivo, ex vivo and U87 mRNA profiles. Samples are imported
with RMA and 3002/54678 probe sets with standard deviation
greater than 1.3 are presented.
(DOCX)
Figure S5 Fold changes (x-axis) and mean methylation
differences (y-axis) between paired in vitro-PT pairs for
both differentially expressed and differentially methylated genes. Differentially expressed genes determined with
paired t-test. Genes with false discovery rate less than 0.05
(Benjamini-Hochberg) and absolute fold change greater than three
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PRMT5 expression for matched PT, in vitro,
in vivo and ex vivo samples. Each column represents a
matched samples and y-axis is the PRMT5 expression value.
(DOCX)

are used. Differentially methylated sites determined with paired
non-parametric Quade test and sites with false discovery rate less
than 0.05 (Benjamini-Hochberg) and absolute methylation
difference greater than 0.3 are colored red and blue others are
colored gray.
(DOCX)

Figure S7

Table S1 List of differentially methylated and differen-

tially expressed genes.
(TXT)

Figure S6 In vitro differentially methylated and differentially expressed 238 genes with fold changes are
uploaded Ingenuity Pathway Analyses software for
functional enrichment. These are the enriched most categories; blue sub-categories are inhibited and orange ones are
activated in vitro.
(DOCX)
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